Successful Treatment Using Simeprevir, Sofosbuvir and Rituximab of a Severe Form of Hepatitis C Virus-related Mixed Cryoglobulinemia with Cardiac Involvement
Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment. New direct-acting antiviral agents have been licensed for HCV under d...
Main Authors: | Rafael Mahieu, Christian Lavigne, Geoffrey Urbanski, Isabelle Fouchard Hubert, Alexandra Ducancelle, Françoise Lunel-Fabiani |
---|---|
Format: | Article |
Language: | English |
Published: |
SMC MEDIA SRL
2015-11-01
|
Series: | European Journal of Case Reports in Internal Medicine |
Subjects: | |
Online Access: | http://ejcrim.com/index.php/EJCRIM/article/view/299 |
Similar Items
-
Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
by: Engy A. Wahsh, et al.
Published: (2018-03-01) -
Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01) -
DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
by: Kamila Abram, et al.
Published: (2023-02-01) -
Mathematical processing of absorption as green smart spectrophotometric methods for concurrent assay of hepatitis C antiviral drugs, Sofosbuvir and Simeprevir: application to combined pharmaceutical dosage forms and evaluation of the method greenness
by: Sayed M. Derayea, et al.
Published: (2023-07-01) -
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service
by: Westerhout KY, et al.
Published: (2017-02-01)